Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. 2015

Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
Division of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK.

MHC anchor residue-modified "heteroclitic" peptides have been used in many cancer vaccine trials and often induce greater immune responses than the wild-type peptide. The best-studied system to date is the decamer MART-1/Melan-A26-35 peptide, EAAGIGILTV, where the natural alanine at position 2 has been modified to leucine to improve human leukocyte antigen (HLA)-A*0201 anchoring. The resulting ELAGIGILTV peptide has been used in many studies. We recently showed that T cells primed with the ELAGIGILTV peptide can fail to recognize the natural tumor-expressed peptide efficiently, thereby providing a potential molecular reason for why clinical trials of this peptide have been unsuccessful. Here, we solved the structure of a TCR in complex with HLA-A*0201-EAAGIGILTV peptide and compared it with its heteroclitic counterpart , HLA-A*0201-ELAGIGILTV. The data demonstrate that a suboptimal anchor residue at position 2 enables the TCR to "pull" the peptide away from the MHC binding groove, facilitating extra contacts with both the peptide and MHC surface. These data explain how a TCR can distinguish between two epitopes that differ by only a single MHC anchor residue and demonstrate how weak MHC anchoring can enable an induced-fit interaction with the TCR. Our findings constitute a novel demonstration of the extreme sensitivity of the TCR to minor alterations in peptide conformation.

UI MeSH Term Description Entries
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
August 2010, Journal of immunology (Baltimore, Md. : 1950),
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
May 2002, Molecular immunology,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
March 1992, Journal of immunology (Baltimore, Md. : 1950),
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
November 2012, Vaccine,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
January 2015, Frontiers in immunology,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
March 2001, Journal of immunology (Baltimore, Md. : 1950),
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
January 1992, Immunologic research,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
March 2009, Molecular immunology,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
September 2017, AIDS research and therapy,
Florian Madura, and Pierre J Rizkallah, and Christopher J Holland, and Anna Fuller, and Anna Bulek, and Andrew J Godkin, and Andrea J Schauenburg, and David K Cole, and Andrew K Sewell
September 2014, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!